Enlivex Therapeutics Ltd.
NASDAQ:ENLVBiotechnology
+$0.19 today
- Market cap
- $71.70M
- Beta
- 1.52
- P/E (TTM)
- 0.0
- EPS (TTM)
- $407.81
Volume 0.06M
Average 0.44M
ENLV EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Enlivex Therapeutics Ltd.NASDAQ: ENLV
EPS (Diluted) · Q4 FY2025 · quarter ended Dec 2025
EPS (Diluted) turns positive
Q4 FY2025 EPS (Diluted) was $386.85, compared with -$3.6 a year earlier. Trailing-twelve-month EPS (Diluted) was $381.9.
Context
- EPS (Diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$0.08 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +3590.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- $386.85+28132.6% QoQ
- Last fiscal yearDec 2025
- $382.2+3590.4% YoY
- LTMDec 2025
- $381.9+3540.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10845.8% | +99.2% | -10746.7 pp |
| 1 year | +3590.4% | -100.0% | -3690.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 382.20 USD
- Year-over-year change
- +3590.4%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 382.20 | +3590.4% |
| FY2024 | 2024-12-31 | (10.95) | +53.2% |
| FY2023 | 2023-12-31 | (23.40) | +32.5% |
| FY2022 | 2022-12-31 | (34.65) | -327.8% |
| FY2021 | 2021-12-31 | (8.10) | — |
EPS (Diluted) vs competitors
How ENLV compares with its peers on the latest reported figures
- ENLV's LTM Dec 2025 EPS (Diluted) of $381.9 is the highest of the 2 companies compared; the peer median is -$0.8.
- Its year-over-year change of +3540.5% is the highest of 2, against a peer median of +35.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Dec 2025 | $381.9 | +3540.5% | — | |
NRXSNeurAxis, Inc. | LTM Mar 2026 | -$0.8 | +35.5% | — |
| Peer median (excluding ENLV) | -$0.8 | +35.5% | — | |
Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 546K | 777K | 835K | 545K | 332K |
| Gross Profit | (546K) | (777K) | (835K) | (545K) | (332K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.88M | 18.69M | 19.24M | 10.13M | 8.92M |
| Selling, General & Admin | 6.24M | 6.7M | 6.14M | 4.91M | 5.69M |
| Operating Expenses | 19.29M | 25.8M | 29.4M | 14.99M | 14.67M |
| Depreciation & Amortization | 546K | 777K | 835K | 545K | 332K |
| EBITDA | (18.74M) | (25.02M) | (28.22M) | (14.47M) | (14.67M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.29M) | (25.8M) | (29.4M) | (15.54M) | (15M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 120K | 835K | 1.57M | 1.07M | 792K |
| Interest Expense | 328K | 5.26M | 14K | 13K | 13K |
| Other Income / Expenses | 4.82M | (5.26M) | 327K | 522K | 1.63B |
| Income Before Tax | (14.47M) | (31.06M) | (29.07M) | (15.01M) | 1.62B |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 382.65M |
| Net Income | (14.47M) | (31.06M) | (29.07M) | (15.01M) | 1.24B |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (8.10) | (34.65) | (23.40) | (10.95) | 405.60 |
| EPS (Diluted) | (8.10) | (34.65) | (23.40) | (10.95) | 382.20 |
| Weighted Avg Shares | 1.19M | 1.23M | 1.24M | 1.37M | 3.05M |
| Weighted Avg Shares (Diluted) | 1.19M | 1.23M | 1.24M | 1.37M | 3.23M |
Enlivex Therapeutics Ltd.
NASDAQ:ENLV
Intrinsic Alpha fair value
Locked
Current Price
$4.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.